Interpreting Tissue Fraction Unbound Across Organs

Why Tissue Fraction Unbound Can Differ Across Organs

A drug can be more strongly bound in one tissue than another because organs do not contain the same proportions of proteins, phospholipids, neutral lipids, water, and other binding environments. That biological variation is one reason organ-specific tissue fraction-unbound estimates matter in PBPK parameterization. But a difference between two reported values does not, by itself, establish a difference in native tissue binding: homogenate dilution, recovery, and assay conditions can also affect the estimates.

The first distinction is between a fraction measured in a diluted tissue homogenate and an estimate corrected to the undiluted tissue. The correction is meaningful only under assumptions about how dilution changes binding capacity. Even a well-corrected estimate remains conditional on the assay and the tissue sample. It should be interpreted alongside the sample preparation and measurement evidence, rather than treated as a direct, assumption-free measurement of binding in a living organ.

What Organ Differences Can Mean

Organ-specific estimates can reflect genuine differences in tissue binding environments. For example, the amount and type of lipid or protein available to interact with a drug can vary across organs. The drug's properties also matter: the same tissue composition need not affect every compound equally. Consequently, a pattern of lower \(f_{u,t}\) in one organ may be compatible with stronger tissue binding there, but the number alone does not identify which tissue constituent caused the difference.

Homogenization makes tissue easier to assay, but it disrupts cellular and subcellular organization. It may also mix compartments that were separated in intact tissue and alter local chemical conditions, including pH. Therefore, a homogenate estimate is not a direct observation of unbound drug in intact tissue. It is an assay-based estimate that requires a defined dilution correction and careful qualification.

For comparisons across organs, consistent methods are essential. Tissue source and handling, homogenate dilution, incubation conditions, drug concentration, and analytical procedures should be comparable or their differences should be documented. A comparison can otherwise confound organ biology with method differences. In addition, \(f_{u,t}\) is a binding parameter, not a measure of total tissue concentration or an organ's tissue-to-plasma partition coefficient. Those quantities address different aspects of distribution.

Correcting a Homogenate Estimate for Dilution

Let \(D\) be the homogenate dilution factor, defined as the total homogenate volume divided by the original tissue volume. Under the standard correction, binding-site concentration in homogenate is reduced by a factor of \(D\) relative to undiluted tissue. If the binding relation is at equilibrium and binding is not concentration-dependent over the relevant range, the corrected fraction is:

The expression \(\frac{1}{f_u}-1\) is the ratio of bound to unbound drug under the fraction-unbound definition. If homogenization reduces the concentration of binding sites by \(D\), then the bound-to-unbound ratio in undiluted tissue is \(D\) times the corresponding ratio in homogenate. Thus:

This justification relies on more than knowing the dilution factor. It assumes that dilution scales binding-site concentration as specified, that binding has reached equilibrium, and that the relevant binding behavior is not materially changed by homogenization or by the altered assay environment. It also assumes that the measured \(f_{u,h}\) is not substantially distorted by drug loss, inadequate recovery, or other assay artifacts. If these assumptions are doubtful, calculating a corrected number does not resolve the underlying problem.

Worked Interpretation: A Difference With Unequal Recovery

Use Composition as Context, Not as Proof

Diagnostics and Common Alternatives

A useful comparison begins with the measurement record, not just the corrected values. Check that the tissue identity, dilution factor, and units were handled consistently; that the incubation was long enough for equilibrium; and that recovery and analytical performance satisfy the method's acceptance criteria. Review whether the tested drug concentration is suitable for the intended interpretation. If binding changes with concentration, a single measured fraction may not represent the same binding regime across samples. Investigate unexpectedly variable replicates, results near the assay's quantification limits, or a strong sensitivity of the corrected estimate to small changes in \(f_{u,h}\).

There are several ways to approach organ differences, each answering a somewhat different question. Comparing raw \(f_{u,h}\) values is straightforward but can be misleading when dilution factors differ. Applying the dilution correction puts estimates on an undiluted-tissue basis, but inherits the correction assumptions. A composition-informed prediction can help assess whether an empirical pattern is plausible, but it depends on the model and its inputs; it does not replace a measurement. Methods using intact tissue may preserve more organization, but they have their own technical constraints and are not directly interchangeable with homogenate estimates without considering what each method measures.

When a corrected estimate is very low, the correction can amplify the effect of measurement error in \(f_{u,h}\). For example, the denominator contains \(1/f_{u,h}\), so small absolute changes in a low measured fraction can produce meaningful changes in the corrected value. Report enough assay detail to judge this sensitivity; do not imply more precision than the measurement supports.

Interpreting the Estimate in Practice

A defensible interpretation separates three claims. First, state the measured homogenate value and the dilution-corrected estimate. Second, state whether the assays were sufficiently comparable and whether the correction assumptions appear reasonable. Third, describe the organ difference at the level the evidence allows: as an observed difference in estimates, as a provisional pattern, or as a pattern compatible with a biological explanation. Avoid turning an assay result into a claim about a specific tissue mechanism or intact-organ exposure without additional evidence.

The main practical value of organ-specific tissue fractions is that they can inform PBPK parameter choices while preserving the distinction between biology and measurement. A table of corrected values is most useful when accompanied by the dilution factor, assay conditions, recovery evidence, and a brief qualification of uncertainty. If two estimates are close relative to assay imprecision, ranking the organs may not be useful. If they differ substantially but were produced under inconsistent conditions, the difference may still be uninterpretable until the methods are reconciled.